Stratos Investment Management LLC Purchases 1,270 Shares of Eli Lilly and Company (NYSE:LLY)

Stratos Investment Management LLC raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 18.1% during the first quarter, according to its most recent filing with the SEC. The firm owned 8,284 shares of the company's stock after purchasing an additional 1,270 shares during the period. Stratos Investment Management LLC's holdings in Eli Lilly and Company were worth $6,842,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of LLY. Blackhawk Capital Partners LLC. lifted its position in shares of Eli Lilly and Company by 41.7% during the 1st quarter. Blackhawk Capital Partners LLC. now owns 8,516 shares of the company's stock valued at $7,033,000 after acquiring an additional 2,504 shares during the period. Black Diamond Financial LLC raised its holdings in Eli Lilly and Company by 35.6% during the first quarter. Black Diamond Financial LLC now owns 2,996 shares of the company's stock worth $2,475,000 after buying an additional 786 shares during the last quarter. May Hill Capital LLC raised its holdings in Eli Lilly and Company by 1.3% during the first quarter. May Hill Capital LLC now owns 1,582 shares of the company's stock worth $1,307,000 after buying an additional 21 shares during the last quarter. Brown Advisory Inc. raised its holdings in Eli Lilly and Company by 1.1% during the first quarter. Brown Advisory Inc. now owns 107,981 shares of the company's stock worth $89,182,000 after buying an additional 1,125 shares during the last quarter. Finally, Consolidated Capital Management LLC acquired a new position in Eli Lilly and Company during the first quarter worth $6,338,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Analyst Ratings Changes

Several research analysts have weighed in on LLY shares. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price objective on the stock. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price objective for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. UBS Group lowered their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Guggenheim restated a "buy" rating and set a $936.00 price objective on shares of Eli Lilly and Company in a report on Friday, June 20th. Finally, Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $1,012.22.

Eli Lilly and Company Price Performance

NYSE:LLY traded up $3.31 during trading hours on Thursday, hitting $790.23. 3,128,711 shares of the stock traded hands, compared to its average volume of 3,670,296. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a market cap of $748.93 billion, a price-to-earnings ratio of 64.30, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40. The stock has a 50 day moving average price of $767.12 and a 200 day moving average price of $800.05.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company's quarterly revenue was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.58 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.76%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.